Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Sharkey

Showing results (31-40 of 111) with videos related to

Pageof 12
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2003
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphomaGary L Griffiths, Serengulam V Govindan, Robert M Sharkey, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 8, 2012
Pretargeting: taking an alternate route for localizing radionuclidesRobert M Sharkey, Chien-Hsing Chang, Edmund A Rossi, et al.
Oncotarget|March 25, 2020
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Bioconjugate Chemistry|August 3, 2011
High-yielding aqueous 18F-labeling of peptides via Al18F chelationChristopher A D'Souza, William J McBride, Robert M Sharkey, et al.
Seminars in Nuclear Medicine|March 31, 2010
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapyRobert M Sharkey, Edmund A Rossi, William J McBride, et al.
Oncotarget|June 24, 2015
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2007
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargetingDavid M Goldenberg, Edmund A Rossi, Robert M Sharkey, et al.
Theranostics|June 28, 2012
Pretargeted molecular imaging and radioimmunotherapyDavid M Goldenberg, Chien-Hsing Chang, Edmund A Rossi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancerRobert M Sharkey, George Hajjar, Dion Yeldell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 23, 2011
Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68GaHabibe Karacay, Robert M Sharkey, William J McBride, et al.
Pageof 12

Showing results (31-40 of 111) with videos related to

Sort By:
Pageof 12
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2003
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphomaGary L Griffiths, Serengulam V Govindan, Robert M Sharkey, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 8, 2012
Pretargeting: taking an alternate route for localizing radionuclidesRobert M Sharkey, Chien-Hsing Chang, Edmund A Rossi, et al.
Oncotarget|March 25, 2020
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Bioconjugate Chemistry|August 3, 2011
High-yielding aqueous 18F-labeling of peptides via Al18F chelationChristopher A D'Souza, William J McBride, Robert M Sharkey, et al.
Seminars in Nuclear Medicine|March 31, 2010
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapyRobert M Sharkey, Edmund A Rossi, William J McBride, et al.
Oncotarget|June 24, 2015
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2007
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargetingDavid M Goldenberg, Edmund A Rossi, Robert M Sharkey, et al.
Theranostics|June 28, 2012
Pretargeted molecular imaging and radioimmunotherapyDavid M Goldenberg, Chien-Hsing Chang, Edmund A Rossi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancerRobert M Sharkey, George Hajjar, Dion Yeldell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 23, 2011
Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68GaHabibe Karacay, Robert M Sharkey, William J McBride, et al.
Pageof 12